Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Other Accumulated Expenses: 2009-2025

Historic Other Accumulated Expenses for China Pharma Holdings (CPHI) over the last 5 years, with Sep 2025 value amounting to $1.6 million.

  • China Pharma Holdings' Other Accumulated Expenses rose 6614.61% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 6614.61%. This contributed to the annual value of $1.6 million for FY2024, which is 26.44% up from last year.
  • Latest data reveals that China Pharma Holdings reported Other Accumulated Expenses of $1.6 million as of Q3 2025, which was up 0.50% from $1.6 million recorded in Q2 2025.
  • China Pharma Holdings' 5-year Other Accumulated Expenses high stood at $3.1 million for Q3 2021, and its period low was $24,000 during Q3 2024.
  • In the last 3 years, China Pharma Holdings' Other Accumulated Expenses had a median value of $1.6 million in 2025 and averaged $1.5 million.
  • As far as peak fluctuations go, China Pharma Holdings' Other Accumulated Expenses plummeted by 97.84% in 2024, and later spiked by 6,614.61% in 2025.
  • Quarterly analysis of 5 years shows China Pharma Holdings' Other Accumulated Expenses stood at $2.8 million in 2021, then decreased by 10.93% to $2.5 million in 2022, then tumbled by 49.29% to $1.3 million in 2023, then climbed by 26.44% to $1.6 million in 2024, then soared by 6,614.61% to $1.6 million in 2025.
  • Its Other Accumulated Expenses was $1.6 million in Q3 2025, compared to $1.6 million in Q2 2025 and $1.6 million in Q1 2025.